Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Merck Global Health Innovation Fund

Investor type Corporate Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 85
Average round size
info
The average size of a deal this fund participated in
$28M
Portfolio companies 53
Rounds per year 6.54
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.38
Exits 21
Key employees 6

Areas of investment

  • Health Care
  • Medical
  • Information Technology
  • Biotechnology
  • Software

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Merck Global Health Innovation Fund:
Typical Co-investors
Merck Global Health Innovation Fund is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Merck Global Health Innovation Fund:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Able Partners New York, New York, United States
Arthavida Ventures -
Daun Penh Cambodia Group -
Ecosummit Berlin, Berlin, Germany
Furneaux Capital Boston, Massachusetts, United States
GKN Redditch, United Kingdom, Worcestershire
Goodwood Capital Fund Canada, Ontario, Toronto
Greater Bay Area Homeland Development Fund China, Hong Kong, Hong Kong Island
Grupo Entregas -
Houde Qianhai Fund China, Guangdong, Shenzhen
Jasper Private Equity Birmingham, England, United Kingdom
Javest Investment Fund Amsterdam, Noord-Holland, The Netherlands
Key Fund England, Sheffield, United Kingdom
Madrona Venture Labs Seattle, United States, Washington
Mayo Clinic Ventures Minnesota, Rochester, United States
Ollerhead Capital -
Service Electric Cablevision -
SINOCHEM GROUP Beijing, Beijing, China
Snapdeal Gurgaon, Haryana, India

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

IndyGeneUS AI

Biotechnology
$50K19 Dec 2022 Washington, District of Columbia, United States

Turbine

Artificial Intelligence
Biopharma
Biotechnology
$23M22 Nov 2022 Budapest, Hungary

Syapse

Big Data
Bioinformatics
Cloud Computing
Health Care
Information Services
Information Technology
SaaS
$35M27 Jul 2022 San Francisco, California, United States

CancerIQ

Analytics
Big Data
Genetics
Information Technology
Medical
SaaS
$14M03 Mar 2022 Chicago, Illinois, United States

Koneksa Health

Analytics
Big Data
Health Care
$45M07 Feb 2022 New York, New York, United States

TagNTrac

Internet of Things
Logistics
PaaS
Supply Chain Management
Wireless
$10M25 Jan 2022 San Diego, California, United States

Verana Health

Analytics
Database
Health Care
$150M14 Jan 2022 San Francisco, California, United States

Transcarent

Family
Health Care
Information Technology
$200M11 Jan 2022 San Francisco, California, United States

Verge Genomics

Bioinformatics
Biotechnology
Genetics
Health Care
Machine Learning
Neuroscience
Therapeutics
$98M16 Dec 2021 San Francisco, California, United States
News
Carlyle and Leading Healthcare-Focused Venture Funds Announce Strategic Growth Investment of up to $430 Million in Saama

– Saama technologies announced a strategic growth investment and will be acquired by Carlyle.
– Saama’s intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies.
– As an end-to-end platform, LSAC provides a unified approach to clinical trial data management and analytics.
– Carlyle has made a strategic growth investment and will acquire a majority stake in the Company.
– A broad co-investor group with several healthcare-focused venture funds, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners, will be investing alongside Carlyle.

Transcarent Raises $58 Million in Series B Funding to Accelerate Consumer-Directed Health and Care Experience for Self-Insured Employers

– Transcarent, a new and different consumer-directed health and care experience for employees of self-insured employers and their families, announced a $58m Series B investment led by General Catalyst and 7wireVentures, with participation from Merck Global Health Innovation Fund, Kleiner Perkins, Leaps by Bayer, GreatPoint Ventures, and Threshold Ventures along with existing investors Alta Partners and Jove Equity Partners.
– This round brings Transcarent’s total funding to $98m and will allow the company to respond to the demand for rapid expansion of its innovative risk-based offering for self-insured employers.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Merck Global Health Innovation Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: